BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10194038)

  • 1. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring.
    Meiser BM; Pfeiffer M; Schmidt D; Reichenspurner H; Ueberfuhr P; Paulus D; von Scheidt W; Kreuzer E; Seidel D; Reichart B
    J Heart Lung Transplant; 1999 Feb; 18(2):143-9. PubMed ID: 10194038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
    Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
    J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection.
    Yamani MH; Starling RC; Goormastic M; Van Lente F; Smedira N; McCarthy P; Young JB
    Transplantation; 2000 Jun; 69(11):2326-30. PubMed ID: 10868634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?
    Meiser BM; Groetzner J; Kaczmarek I; Landwehr P; Müller M; Jung S; Uberfuhr P; Fraunberger P; Stempfle HU; Weis M; Reichart B
    Transplantation; 2004 Aug; 78(4):591-8. PubMed ID: 15446320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.
    Eckhoff DE; McGuire BM; Frenette LR; Contreras JL; Hudson SL; Bynon JS
    Transplantation; 1998 Jan; 65(2):180-7. PubMed ID: 9458011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative introduction and maintenance immunosuppression therapy of oral-only tacrolimus, mycophenolate mofetil and steroids reduce acute rejection episodes after lung transplantation.
    Bittner HB; Barten MJ; Binner C; Lehmann S; Garbade J; Hammerschmidt S; Wirtz H; Mohr FW
    Eur J Cardiothorac Surg; 2010 Sep; 38(3):268-76. PubMed ID: 20304665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation.
    Roan JN; Chou CH; Hsu CH; Wu SY; Huang YC; Yang YJ; Luo CY
    Ann Transplant; 2013 Feb; 18():43-52. PubMed ID: 23792500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation.
    Wlodarczyk Z; Vanrenterghem Y; Krämer BK; Squifflet JP; Ostrowski M
    BMC Nephrol; 2012 Jul; 13():68. PubMed ID: 22835011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil in pancreas transplantation.
    Gruessner RW; Sutherland DE; Drangstveit MB; Wrenshall L; Humar A; Gruessner AC
    Transplantation; 1998 Aug; 66(3):318-23. PubMed ID: 9721799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
    Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
    Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels.
    Meiser BM; Pfeiffer M; Schmidt D; Ueberfuhr P; Reichenspurner H; Paulus D; von Scheidt W; Kreuzer E; Seidel D; Reichart B
    Transplant Proc; 1999; 31(1-2):84-7. PubMed ID: 10083018
    [No Abstract]   [Full Text] [Related]  

  • 18. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA; Lawen J; Daley C
    Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.